IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy

0578373 - ÚMG 2024 RIV GB eng J - Článek v odborném periodiku
Niederlová, Veronika - Tsyklauri, Oksana - Kovář, Marek - Štěpánek, Ondřej
IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.
Trends in Immunology. Roč. 44, č. 11 (2023), s. 890-901. ISSN 1471-4906. E-ISSN 1471-4981
Grant CEP: GA ČR GA22-21356S; GA ČR(CZ) GA22-20548S; GA MŠMT(CZ) LX22NPO5103; GA MŠMT LX22NPO5102
GRANT EU: European Commission(XE) 802878 - FunDiT
Výzkumná infrastruktura: e-INFRA CZ II - 90254
Institucionální podpora: RVO:68378050 ; RVO:61388971
Klíčová slova: cancer * cytotoxic T cells * il-2 * immunotherapy * pd-1 * regulatory T cell
Obor OECD: Immunology; Immunology (MBU-M)
Impakt faktor: 16.8, rok: 2022
Způsob publikování: Open access
https://www.sciencedirect.com/science/article/pii/S1471490623001953?via%3Dihub

The therapeutic potential of interleukin (IL)-2 in cancer treatment has been known for decades, yet its widespread adoption in clinical practice remains limited. Recently, chimeric proteins of an anti-PD-1 antibody and suboptimal IL-2 variants were shown to stimulate potent antitumor and antiviral immunity by inducing unique effector CD8+ T cells in mice. A similar subset of cytotoxic T cells is induced by depletion of regulatory T cells (Tregs), suggesting IL-2 sequestration as a major mechanism through which regulatory T cells suppress activated CD8+ T cells. Here, we present our view of how IL-2-based biologicals can boost the antitumor response at a cellular level, and propose that the role of Tregs following such treatments may have been previously overestimated.
Trvalý link: https://hdl.handle.net/11104/0347367